1)木内良明:緑内障治療薬の選択基準と治療指針―緑内障の薬物治療の第1選択には何を選ぶか.眼科 43:155-161,2001
2)Bron AM, Denis P, Nordmann JP et al:Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 79:289-293, 2001
3)Van Buskirk EM:Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol 88:739-743, 1979
4)Inoue K, Okugawa K, Kato S et al:Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 12:480-485, 2003
5)McMahon CD, Shaffer RN, Hoskins HD Jr et al:Adverse effects experienced by patients taking timolol. Am J Ophthalmol 88:736-738, 1979
6)Shoji N, Ogata H Suyama H et al:Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension:an uncontrolled, open-label study. Curr Med Res Opin 21:503-508, 2005
7)March WF, Ochsner KI:The long-term safety and efficacy of brinzolamide 1.0%(azopt)in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 129:136-143, 2000
8)Tanimura H, Minamoto A, Narai A:Corneal edema in glaucoma patients after the addition of brinzolamide 1% ophthalmic suspension. Jpn J Ophthalmol 49:332-333, 2005
9)安藤 彰・宮崎秀行・福井智恵子・他:炭酸脱水酵素阻害薬点眼後に不可逆的な角膜浮腫をきたした1例.臨眼 59:1571-1573,2005
10)Miyata K, Amano S, Sawa M et al:A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol 121:1537-1539, 2003
11)廣岡一行・馬場哲也・竹中宏和・他:開放隅角緑内障におけるラタノプロストへのチモロールあるいはブリンゾラミド追加による眼圧下降効果.あたらしい眼科 22:809-811,2005
12)Boger WP Ⅲ:Shortterm“escape”and longterm“drift”. The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol 28:235-242, 1983
13)中井倫子・井上賢治・中井義幸・他:β遮断薬からブリンゾラミド点眼への変更の短期効果.あたらしい眼科 23:911-916,2006
14)Wilkerson M, Cyrlin M, Lippa EA et al:Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 111:1343-1350, 1993
15)Inoue K, Wada S, Wakakura M et al:Switching from dorzolamide to brinzolamide:effect on intraocular pressure and patient comfort. Jpn J Ophthalmol 50:62-80, 2006
16)Krupin T, Sly WS, Whyte MP et al:Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydraseⅡ deficiency. Am J Ophthalmol 99:396-399, 1985
17)DeSantis L:Preclinical overview of brinzolamide. Surv Ophthalmol 44:S119-S129, 2000
18)井上賢治・庄司治代・若倉雅登・他:ブリンゾラミドの角膜内皮への影響.臨眼 60:183-187,2006
19)Lichter PR, Newman LP, Wheeler NC et al:Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol 85:495-502, 1978